Biogen is an intriguing stock that occupies one of the leading positions in the central nervous system therapeutic market.

Earnings Call Insights: Biogen Inc. (BIIB) Q1 2025 Management View CEO Chris Viehbacher highlighted Biogen's evolving portfolio, with newer products such as LEQEMBI, SKYCLARYS, and ZURZUVAE now ...

The FDA label update boosts GE HealthCare’s Vizamyl to a market advantage despite the emergence of blood-based tests.

Acquisitions involving innovator drugs have grown year-on-year with total deal value increasing eight-fold to almost $18 ...

Uptake of Biogen’s breakthrough Alzheimer’s drug, Leqembi, appears to be picking up, with roughly $40 million in sales for the quarter.

Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...

Leqembi’s $40 million in Q2 sales beat analyst expectations, as it had a slow uptake – bringing in just $10 million last year following its launch. Earlier this year, Biogen said about 5,000 people ...

Skyclarys is an important growth product for Biogen, which has been hit in the last few years by a series of pipeline ...

Biogen posted fourth-quarter revenue and profit that topped expectations as its cost cuts showed progress and new products, including its breakthrough Alzheimer's treatment Leqembi, saw growth ...

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has announced that Japanese ...

A U.K. health agency said the Alzheimer's drugs Kisunla and Leqembi are not cost-effective, meaning they won't be offered through the NHS.